Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...

HYDERABAD: India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of ...

(NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2024 and highlighted recent ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

THE US headquartered clinical research firm Celerion has announced it will relocate its Belfast operation to the new Queen’s ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical ...

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 ...

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...

Q4 2024 Earnings Call Transcript February 26, 2025 Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.08. Operator: Ladies and gentlemen, good ...